Author Archives: William Looney

13 Years Right: Behind This Year’s Pharm Exec Industry Audit

Pharm Exec‘s 13th Industry Audit looks at how well a cross section of companies in big Pharma, mid-tier specialty and biotech are delivering against today’s hottest performance metric: shareholder value. When we began the series back in September 2002, this kind of broad indicator—indeed the very concept of “value”—was often discounted by the investment community in […]
Posted in Strategy | Tagged , , | Leave a comment

Emerging Pharma Leaders: Michael Injaychock, Eli Lilly & Co.

Michael Injaychock joined Eli Lilly in 2007 after five years in a Washington-based financial services consulting role and a subsequent MBA from the University of North Carolina. Course work there as well as a stiff self-evaluation of his former job led Injaychock to conclude his future lay in a post that carried a larger purpose. “I […]
Posted in leadership, People | Tagged , , | Leave a comment

Brown University’s Executive Masters in Healthcare Leadership: A Mission to Transform

Mid-career students at Brown University’s new Executive Masters in Healthcare Leadership program are challenging the status quo with workplace projects focused on one thing: removing the organizational silos that slow innovations in the delivery and financing of healthcare. As the US healthcare system stumbles toward a new consensus built around the “triple aim” of increased […]
Posted in Strategy | Tagged , , | Leave a comment

Pharm Exec's 2014 Dealmakers Outlook

After fading to dreary summer stock for the past few years, dealmaking is today back to center stage, but with the major roles reversed— small biotech, yesterday’s understudy, now gets top billing, while big Pharma has to work harder for its close-up. Pharm Exec brought partner Campbell Alliance and a select group of West Coast […]
Posted in Deals, Global, Strategy | Tagged , , , | Leave a comment

BIO 2014 Takeaway: The Peace Dividend

A surprising take away from the BIO International Convention in San Diego last month is the stark contrast between cooperative industry engagement and an unstable geopolitical order marked by xenophobia, drift and active, often violent government disengagement from the hard work of building common ground. While BIO held 29,000 partnering meetings over four days, convened […]
Posted in Biotech, Emerging Markets, Europe, Events, Global | Tagged , , | Leave a comment
  • Categories

  • Meta